Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS. METHODS: In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an additional 10 weeks. The primary end point, the proportion of patients who had adequate relief of global IBS symptoms, and the key secondary end point, the proportion of patients who had adequate relief of IBS-related bloating, were assessed weekly. Adequate relief was defined as self-reported relief of symptoms for at least 2 of the first 4 weeks after treatment. Other secondary end points included the percentage of patients who had a response to treatment as assessed by daily self-ratings of global IBS symptoms and individual symptoms of bloating, abdominal pain, and stool consistency during the 4 weeks after treatment and during the entire 3 months of the study. RESULTS: Significantly more patients in the rifaximin group than in the placebo group had adequate relief of global IBS symptoms during the first 4 weeks after treatment (40.8% vs. 31.2%, P=0.01, in TARGET 1; 40.6% vs. 32.2%, P=0.03, in TARGET 2; 40.7% vs. 31.7%, P<0.001, in the two studies combined). Similarly, more patients in the rifaximin group than in the placebo group had adequate relief of bloating (39.5% vs. 28.7%, P=0.005, in TARGET 1; 41.0% vs. 31.9%, P=0.02, in TARGET 2; 40.2% vs. 30.3%, P<0.001, in the two studies combined). In addition, significantly more patients in the rifaximin group had a response to treatment as assessed by daily ratings of IBS symptoms, bloating, abdominal pain, and stool consistency. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools. (Funded by Salix Pharmaceuticals; ClinicalTrials.gov numbers, NCT00731679 and NCT00724126.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Placebo-controlled studies of antibiotic (rifaximin) treatment in FGIDs and IBS have demonstrated significant reduction in bloating scores with rifaximin compared to placebo150–152.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A short course of a non-absorbable antibiotic such as rifaximin has been shown to moderately improve the symptoms of irritable bowel syndrome (IBS), particularly bloating and flatulence.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, it is likely that patients may require repeated courses of therapy, as trial evidence suggests the benefit diminishes by 12 weeks.189”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The sample size calculation was based on a one-sided α level of 0·0125 to account for two primary end points, an assumed placebo response rate of 40 % and a treatment difference of 10 % in responder rates based on previously published studies( 23 , 28 ). Further, accounting for a potential 10 % dropout rate and three interim analyses, 580 subjects in each group were required, totalling to 1740 sub”
From Effect of the probiotic strain Bifidobacterium animalis subsp. lactis , BB-12 ® , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial (2015) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, treatments that change the microbiota, such as antibiotics or fecal microbiota transplant, 19,20 may be bene fi cial in a subset of patients with IBS.”
From Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis (2023) · cites this paper as [19]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Self-citationPimentel, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05902-6 · Cited by 669
Self-citationSmall intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00004 · Cited by 466
Self-citationSharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344
Attar, A., Flourié, B., Rambaud, J., Franchisseur, C., Ruszniewski, P., & Bouhnik, Y. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70336-7 · Cited by 234
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Self-citation
Research works printed but not linked: 1
- El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health- related quality of life. Rev Gastroenterol Disord 2003;3:Suppl 2:S3-S11.
Cited by
Items 601–700 of 1,000
From IBS to DBS: The Dysbiotic Bowel Syndrome
Benno, P., Dahlgren, A., Befrits, R., Norin, E. L., Hellström, P. M., & Midtvedt, T. (2016) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709616648458 · Cited by 12
Gupta, K., Ghuman, H. S., & Handa, S. (2017) · Clinical Medicine Insights Gastroenterology · doi:10.1177/1179552217728905 · Cited by 14
Mokha, J. S., & Hyams, J. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-43268-7_37 · Cited by 10
Brown, K., Scott-Hoy, B., & Jennings, L. W. (2016) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v7.i3.463 · Cited by 8
An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D.
Lacy, B. E., Chey, W. D., & Chang, L. (2013) · Europe PMC (PubMed Central) · Cited by 9
Self-citationAdherence to Short-course Pharmacotherapy in Adults with Irritable Bowel Syndrome
Sherwin, L. B., Deroche, C. B., Krisanabud, P., Matteson, M., Bechtold, M. L., & Ruppar, T. M. (2019) · Western Journal of Nursing Research · doi:10.1177/0193945919872419 · Cited by 11
“In large multicenter studies, rifaximin has been found to reduce the symptom of pain in those with IBS-D (Pimentel et al., 2011).”
BackgroundInfluentialAn Overview of Gastrointestinal Dysfunction in Parkinsonian Syndromes
Talman, L. S., & Safarpour, D. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1771461 · Cited by 8
Evaluation and Treatment of Colonic Symptoms
Pasanen, M. E. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.01.009 · Cited by 8
“Testing on patients with IBS can show abnormal hydrogen and some patients respond to rifaximin, which suggests alteration in bacterial distribution.(18,19) Treatments found to be effective in symptommanagement include exercise, antispasmodics, rifaximin, and probiotics.”
BackgroundClinical Response of Rifaximin Treatment in Patients with Abdominal Bloating
Yoon, K., Kim, N., Lee, J. Y., Oh, D. H., Seo, A. Y., Yun, C. Y., Yoon, H., Shin, C. M., Park, Y. S., & Lee, D. H. (2018) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2018.72.3.121 · Cited by 9
“9%, respectively).(22) Another retrospective study for non-constipated IBS subjects reported that as high as 75% of patients had clinical improvement.”
Seyedian, S., Hajiani, E., Masjedizadeh, A., Shayesteh, A., & Babazadeh, S. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_464_18 · Cited by 13
“In addition, the gastrointestinal symptoms improved after this diet.[20] Since the disease persists for a long time and the effects of long‐term treatments have not been established, the diet will be effective in controlling the symptoms of these patients.”
Laskaratos, F., Goodkin, O., Thoua, N. M., & Murray, C. D. (2015) · Medicine · doi:10.1016/j.mpmed.2015.02.010 · Cited by 9
Camilleri, M., & Szarka, L. A. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06776-4 · Cited by 8
“Finally, though antibacterial agents, particularly rifaximin [8], may improve bloating in irritable bowel syndrome (IBS) patients, it is unclear that such a response results from actually treating SIBO since the composition of the gut microbiome does not significantly differ from that of subjects receiving placebo in…”
BackgroundSato, T., Honda, S., Tominaga, Y., Miyakoshi, Y., Ueda, T., & Sawashita, J. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10614 · Cited by 7
Algorithms or biomarkers in patients with lower DGBI ?
Camilleri, M., & Yang, D. Y. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14856 · Cited by 7
Zheng, L., Lu, W., Xiao, Q., Lai, Y., Fan, H., Sun, Y., Huang, D., Wang, Y., Li, Z., Jiang, Z., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92990-7 · Cited by 10
Hong, G., Li, Y., Yang, M. J., Li, G., Jin, Y. T., Xiong, H., Qian, W., & Hou, X. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2022.2136013 · Cited by 8
“such as post-infectious IBS induced by acute enteritis [4], alleviation of IBS symptoms after using antibiotics [5].”
BackgroundSurvey-Based Analysis of the Clinical Treatment Status of Irritable Bowel Syndrome in Korea
Koo, H. S., Son, H. C., Lee, H. S., Goong, H. J., Kim, J., Kim, K. B., Kwon, Y. H., Kim, J. H., Shin, H. D., Shin, J., et al. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e126 · Cited by 7
Irritable Bowel Syndrome: Peripheral Mechanisms and Therapeutic Implications
Crisan, I. M., & Dumitrascu, D. L. (2014) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-269 · Cited by 7
“Two phase III, double-blind, placebocontrolled trials (TARGET 1 and TARGET 2) that included IBS patients without constipation randomly assigned to rifaximin or placebo showed that rifaximin significantly improved symptoms like abdominal pain, bloating and diarrhea [69].”
Opportunities for Cost Reduction of Medical Care: Part 3
Malach, M., & Baumöl, W. J. (2012) · Journal of Community Health · doi:10.1007/s10900-011-9534-8 · Cited by 7
“The treatment of Clostridium difficile diarrhea and irritable bowel syndrome with rifaximin (Xifaxan ) has decreased hospital stays and associated costs [34].”
BackgroundStool as a treatment for IBS: more questions than answers?
Ford, A. C. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30337-0 · Cited by 8
Advancements in drug development for diarrhea-predominant irritable bowel syndrome
Dothel, G., Barbaro, M. R., Raschi, E., Barbara, G., & Ponti, F. D. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1442434 · Cited by 7
“Reporting of adverse events (AEs) was comparable to the placebo group and no episode of ischemic colitis or Clostridium difficile infection occurred [35].”
Almario, C. V., Noah, B. D., Jusufagic, A., Lew, D., & Spiegel, B. M. R. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.03.025 · Cited by 7
Inflammatory Bowel Disease and Irritable Bowel Syndrome: What to Do When There Is an Overlap
Kamal, A., Padival, R., & Lashner, B. A. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy277 · Cited by 9
Sun, M., Sun, L., Guo, G., & Zhang, S. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12775 · Cited by 7
A Practical Approach to the Diagnosis and Treatment of Abdominal Bloating and Distension.
Cangemi, D. J., & Lacy, B. E. (2022) · PubMed · Cited by 9
The Lactulose Breath Test in Irritable Bowel Syndrome: Is It All Hot Air?
Burgell, R., & Gibson, P. R. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3956-6 · Cited by 7
“of patients develop irritable bowel syndrome (IBS) after suffering from a gastrointestinal infection, and 40 % describe symptomatic benefit from antibiotic therapy [1].”
BackgroundGut microbiota: origin or panacea for all ills? Gut microbiota and systemic diseases
Colica, C., Vecchio, I., Aiello, E., Abenavoli, L., Scarlata, G. G. M., & Aiello, V. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108299 · Cited by 9
Medical Therapies for Diarrhea-Predominant Irritable Bowel Syndrome
Sayuk, G. S. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.04.003 · Cited by 8
Bouveret's syndrome and digestive endoscopy as diagnostic support
Martínez, A. G., Millán, D. M., Prado, Á. M., & García, J. P. (2024) · Revista Andaluza de Patología Digestiva · doi:10.37352/2024471.4 · Cited by 5
The place of eluxadoline in the management of irritable bowel syndrome with diarrhea
Levio, S., & Cash, B. D. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17721152 · Cited by 6
Daghaghzadeh, H., Memar, A., Mohamadi, Y., Rezakhani, N., Safazadeh, P., Aghaha, S., & Adibi, P. (2018) · PubMed Central · doi:10.4103/jrpp.jrpp_17_56 · Cited by 9
“This article is a placebo-controlled clinical trial to assess the therapeutic effects of low-dose bismuth subcitrate on symptoms and the health-related quality of life in adult patients with IBS.”
BackgroundInfluentialde Arce, E. P., Quera, R., & Quigley, E. M. M. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.03.008 · Cited by 6
Quach, D. T., Vu, K. T., & Vu, K. V. (2021) · JGH Open · doi:10.1002/jgh3.12616 · Cited by 12
Zhang, J., Zhang, C., Zhang, T., Zhang, L., & Duan, L. (2023) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm22182 · Cited by 6
Challenges of Multimorbidities in the Era of an Aging Population
Jung, M. (2016) · The Health Care Manager · doi:10.1097/hcm.0000000000000106 · Cited by 8
“Individuals with multimorbidities are liable to suffer from mental diseases.(6) When academic evidence of multiple chronic diseases is insufficient, clinical guidelines and the success of treatments are unclear.”
BackgroundNew therapies in Irritable Bowel Syndrome: what works and when
Craig, O. F. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000411 · Cited by 9
Zheng, Y., Obeng, S., Wang, H., Stevens, D. L., Komla, E., Selley, D., Dewey, W., Akbarali, H., & Zhang, Y. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00234 · Cited by 6
Lior, O., Sklerovsy-Benjaminov, F., Lish, I., Konokoff, F., & Naftali, T. (2019) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2019.75018 · Cited by 7
“Treatment options might include non-medical approaches such as dietary modifications, change in lifestyle and cognitive behavior therapy [4] medical approaches include drugs such as laxatives, lubiproston [5] linaclotide, antidiarrheals, alosetron, rifaximin [6], and eluxadoline [7].”
BackgroundStemboroski, L. N., & Schey, R. (2020) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2020.05.001 · Cited by 6
Kruis, W., Poškus, T., Böhm, G., Bunganič, I., Rácz, I. A., Frățilă, O., Barbara, G., Wehrum, S., Nacak, T., & Greinwald, R. (2020) · GastroHep · doi:10.1002/ygh2.426 · Cited by 6
Rifaximin antibiotic treatment for restless legs syndrome: a double-blind, placebo-controlled study
Weinstock, L. B., & ZEISS, S. (2012) · Sleep and Biological Rhythms · doi:10.1111/j.1479-8425.2012.00537.x · Cited by 6
Hanaway, P. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1793-8.00040-6 · Cited by 6
Definitions and Classifications of Irritable Bowel Syndrome
Ford, A. C. (2013) · Wiley eBooks · doi:10.1002/9781118444689.ch1 · Cited by 6
The Human Microbiome in Health and Disease
Hill, C. J., Ross, R. P., Stanton, C., & O’Toole, P. W. (2016) · Wiley eBooks · doi:10.1002/9783527682386.ch4 · Cited by 7
Bajaj, J. S., Brenner, D. M., Cai, Q., Cash, B. D., Crowell, M. D., DiBaise, J. K., Gallegos-Orozco, J. F., Gardner, T. B., Gyawali, C. P., Ha, C. Y., et al. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000709 · Cited by 6
Self-citationMicrobial Influences on Irritable Bowel Syndrome
Quigley, E. M. M. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2024.12.003 · Cited by 5
Leite, G., Rezaie, A. R., Morales, W., Weitsman, S. R., Germano, J. D. F., Barlow, G. M., Parodi, G., Pimentel, M. L., Villanueva-Millán, M. J., Sanchez, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-69162-4 · Cited by 5
Self-citationEmerging drug for diarrhea predominant irritable bowel syndrome
Deiana, S., Gabbani, T., Bagnoli, S., & Annese, V. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1013935 · Cited by 6
Memory Reflections of the Microbiota-Gut and Oligodendrocyte Axis
Ray, S. K., & Mukherjee, S. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273256132230921103333 · Cited by 6
Le syndrome de l’intestin irritable : nouvelles pistes physiopathologiques et conséquences pratiques
Duboc, H., Dior, M., & Coffin, B. (2016) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2015.12.030 · Cited by 8
Jalanka, J., & Spiller, R. E. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13194 · Cited by 7
Munjal, A., Dedania, B. K., & Cash, B. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691524 · Cited by 6
Lee, S. D., Singla, A., Rulyak, S. J., & Clark‐Snustad, K. (2020) · GastroHep · doi:10.1002/ygh2.416 · Cited by 5
Safwat, E., Salah, M. M., & Hussein, H. A. (2020) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2020.08.003 · Cited by 6
Lee, H. J., & Park, K. S. (2017) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2017.70.6.288 · Cited by 5
Poortmans, P. J., & Kindt, S. (2020) · VUBIR (Vrije Universiteit Brussel) · Cited by 9
An analysis of gut dysbiosis in obesity, diabetes, and chronic gut conditions
Haleem, A., Anvari, S., Nazli, A., Sager, M., & Akhtar, M. (2020) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.4103/ijmbs.ijmbs_102_20 · Cited by 5
Novoa-Farías, O., Frati-Munari, A. C., Peredo, M. A., Flores-Juárez, S., Novoa-García, O., Galicia-Tapia, J., & Romero-Carpio, C. E. (2016) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2015.12.001 · Cited by 5
[The expression of cMET/hepatocyte growth factor receptor in colorectal cancer].
Ajisaka, H., Nishimura, G., Tsuneda, A., Fujita, H., Michiwa, Y., Kawamura, T., Sato, T., Nojima, N., Fushida, S., Fujimura, T., et al. (1998) · PubMed · Cited by 6
Cada, D. J., Levien, T. L., & Baker, D. E. (2013) · Hospital Pharmacy · doi:10.1310/hpj4802-143 · Cited by 4
Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?
Ponziani, F. R., Pompili, M., & Gasbarrini, A. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4656-1 · Cited by 5
“rifaximin at the dose of 550 mg tid for 2 weeks is superior to placebo in improving IBS-D symptoms such as bloating, abdominal pain, and altered stool consistency over the 10-week study period, with a good safety profile [2].”
Weerts, Z. Z. R. M., Heinen, K. G. E., Masclee, A., Quanjel, A. B. A., Winkens, B., Vork, L., Rinkens, P. E. L. M., Jonkers, D. M. A. E., & Keszthelyi, D. (2021) · JMIR mhealth and uhealth · doi:10.2196/27998 · Cited by 5
Irritable Bowel Syndrome: from diagnostic criteria to targeted treatment
Weerts, Z. Z. R. M. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20211015zw · Cited by 5
All in my head or all in my gut? An update on irritable bowel syndrome
Woods, A. T., Ford, A. C., & Black, C. J. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001141 · Cited by 4
IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
Šuran, J., Pavlović, N., Božić, J., Kumrić, M., Vukojević, K., Filipović, N., & Radić, B. (2026) · Antibiotics · doi:10.3390/antibiotics15030251 · Cited by 6
“However, this specific trial did not confirm the presence or eradication of SIBO in its participants [20].”
Treatment of Irritable Bowel Syndrome with Predominant Diarrhea
Kim, M. C., Park, Y., Lee, H. S., & the Korean Society of Neurogastroenterology and Motility (2025) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2025.011 · Cited by 5
Rokkas, T., Ekmektzoglou, K. A., Tsanou, E., Bricca, L., Menni, A.-E., Golfakis, P., & Kotzampassi, K. E. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003062 · Cited by 7
Síndrome del intestino irritable: lo (pen)último sobre lo que se está investigando
Domingo, J. J. S. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.10.010 · Cited by 4
Castiglione, R., Bertino, G., Vicari, B. O., Rizzotto, A., Sidoti, G., D’Agati, P., Salemi, M., Malaguarnera, G., & Vicari, E. S. D. (2024) · Diseases · doi:10.3390/diseases12100260 · Cited by 4
“…but they can also produce extraintestinal symptoms, in which case the clinical presentation can be classified in a phenotyping system based on which of the following six domains are affected: urinary, psychosocial, organ-specific, infection, neurologic/systemic, and tenderness (UPOINT) [41–43].”
BackgroundKlemm, N. K., & Moosavi, S. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08716-y · Cited by 7
Deng, N., Xie, S., Liu, Q., Peng, H., Fang, L., Shen, J., & Lin, X. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1549617 · Cited by 4
“Multiple studies support the signi fi cant role of gut microbiota dysbiosis in the pathogenesis of IBS (Ghoshal and Srivastava, 2014; Ghoshal et al., 2016; Pimentel et al., 2011).”
Proton-pump inhibitor therapy and small bowel bacterial contamination
Hamvas, J. (2012) · Orvosi Hetilap · doi:10.1556/oh.2012.29419 · Cited by 4
The Use of Non-Narcotic Pain Medication in Pediatric Gastroenterology
Miranda, A., & Saps, M. (2014) · Pediatric Drugs · doi:10.1007/s40272-014-0080-6 · Cited by 4
Yang, L., Lu, Y., Haifeng, Z., Ma, X., Bao, C., Wu, H., Chen, Z., Guanghong, D., Li, Q., & Zhou, S. (2017) · 中医杂志:英文版 · doi:10.1016/s0254-6272(17)30161-9 · Cited by 4
Bloating and Abdominal Distension: Exploring Hidden Depths and Insights
Pichetshote, N., & Rezaie, A. R. (2020) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-020-00288-w · Cited by 5
Mahd-Ab.lah, N., Kueh, Y. C., Kuan, G., Yahaya, F. H., Wong, M. S., Samat, N. A. A., Hamid, N., Nor, N. M., Whitehead, W. E., Thiwan, S. I., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18052487 · Cited by 4
Syndrome de l’intestin irritable: Rôle du microbiote intestinal
Lajoie, F., Rousseau, G., Blanquet‐Diot, S., & Etienne‐Mesmin, L. (2021) · médecine/sciences · doi:10.1051/medsci/2021095 · Cited by 7
Razmjoo, S., Bagheri, A., Shahbazian, H., Hosseini, S.-M., & Ebrahimian-Tabrizi, F. (2021) · Journal of Contemporary Brachytherapy · doi:10.5114/jcb.2021.108597 · Cited by 4
“Several studies have investigated effects of antibiotics in reducing the intestinal bacterial load and thus decreasing bowel gas [23-29].”
BackgroundZeisler, B., & Hyams, J. S. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-709-9_34 · Cited by 4
Guarner, F. (2011) · Colloquium Series on Integrated Systems Physiology From Molecule to Function · doi:10.4199/c00047ed1v01y201110isp029 · Cited by 6
“Recently, the use of non-absorbable oral antibiotics has been proposed as treatment for alleviating symptoms of patients with irritable bowel syndrome without constipation (Pimentel et al., 2011).”
BackgroundRifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Talley, N. J. (2011) · Yearbook of Medicine · doi:10.1016/s0084-3873(11)00321-x · Cited by 4
It’s All in the Mix: Diagnosis and Management of Food Intolerance
Philpott, H., Yu, S., & Rao, S. S. C. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.03.005 · Cited by 4
Development of an In Vitro Fermentation Model to Culture the Human Distal Gut Microbiota
McDonald, J. A. K. (2013) · The Atrium (University of Guelph) · Cited by 8
Vitta, S., & Sayuk, G. (2018) · Alimentary Pharmacology and Therapeutics · doi:10.1111/apt.14902 · Cited by 6
“4).(4,5) Though methodologically sound, this study does deviate from current European and US endpoint guidance for IBS-D trials (requiring combined abdominal pain and stool consistency improvements) and study duration.”
ResultShin, A., Xing, Y., Waseem, M. R., Siwiec, R. M., James-Stevenson, T. N., Rogers, N. A., Bohm, M. E., Wo, J. M., Lockett, C. J., Gupta, A., et al. (2024) · medRxiv · doi:10.1101/2024.01.31.24302084 · Cited by 4
Biomarkers in Irritable Bowel Syndrome
Guan, M., & Chang, L. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2025.08.002 · Cited by 4
Ghoshal, U. C., Ramakrishna, B., Rathi, P. M., Shukla, A., Panigrahi, M. K., Jain, S., Saha, I., Chakravartty, K., Singh, M., Mustafa, U., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70137 · Cited by 3
“The secondary outcome measures such as individual symptom subscores and QOL have also been proposed and reported earlier [18, 31].”
Rifaximin’s therapeutic spectrum: approved indications and experimental insights into emerging uses
Palenca, I., Franzin, S. B., Pesce, M., Sarnelli, G., & Esposito, G. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00830-0 · Cited by 6
“Its approved indications include: Traveler’s diarrhea (200 mg three times daily for 3 days) [ 10]; hepatic encephalopathy (550 mg twice daily for recurrence prevention) [ 11]; Irri - table bowel syndrome with diarrhea (IBS-D) (550 mg three times daily for 14 days) [ 12 ].”
Diarrhea management: from pathophysiology to microbiota modulation
Marasco, G., Meacci, D., Sarnelli, G., Tosetti, C., Cremon, C., Savarino, E. V., & Barbara, G. (2026) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848261424324 · Cited by 5
“143 However, since many patients experienced symptom relapse after a few weeks, the TARGET 3 trial evaluated the efficacy and the safety of retreatment with rifaximin.”
Role of antispasmodics in the treatment of irritable bowel syndrome
Drozdov, V. N., Arefev, K. I., Serebrova, S. Y., Комиссаренко, И. А., Ших, Е. В., & Starodubtsev, A. K. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-5-155-164 · Cited by 4
Primer consenso centroamericano y del Caribe del síndrome de intestino irritable
Galdámez, J., Aguilar-Paiz, L., Blanco, G. M., Monge, S. C., de Mezerville-Cantillo, L., Castillo, P. N., Quintero, I., Polanco, E. D. P. R., Hernández, M. A. S., Sandoval, E., et al. (2023) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/agl.v53i2.272 · Cited by 4
“La mejoría se mantuvo significativamente mayor en el grupo de tratamiento durante todo el periodo de estudio.(119) El ensayo clínico multicéntrico doble ciego, aleatorizado y controlado con placebo TARGET 3 evaluó ciclos de tratamiento repetidos y a largo plazo con rifaximina en pacientes con SII-D.”
BackgroundShah, Q., & Soldera, J. (2026) · World Journal of Methodology · doi:10.5662/wjm.v16.i1.107169 · Cited by 5
Pathophysiological approach to chronic diarrhoea
Corazziari, E. S. (2012) · Internal and Emergency Medicine · doi:10.1007/s11739-012-0820-y · Cited by 3
Targeting the microbiota in the management of gastrointestinal and liver disease.
Quigley, E. M. M., & Monsour, H. (2013) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · doi:10.47892/rgp.2013.332.219 · Cited by 3
Assessing the Population Impact of Published Intervention Studies
Coffinier, C., Teutsch, S. M., & Fielding, J. E. (2015) · NAM Perspectives · doi:10.31478/201506e · Cited by 3
'Functional' gastrointestinal disorders—a paradigm shift
Talley, N. J. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.163 · Cited by 3
Meyer, R. P., Werthmann, P. G., & Kienle, G. S. (2018) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2018.03.013 · Cited by 3
Exocrine pancreatic insufficiency and causes of abdominal symptoms in diabetes patients
Kadaj-Lipka, R., & Rydzewska, G. M. (2020) · Gastroenterology Review · doi:10.5114/pg.2020.101556 · Cited by 5
“The results indicate that abdominal symptoms in diabetic patients are more commonly associated with bacterial overgrowth (SIBO) [19].”
BackgroundInfluentialFunctional Gastrointestinal Disorders in Patients with Inflammatory Bowel Disease
Kim, K. O. (2022) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2022.001 · Cited by 3
Ткач, С. М., & Dorofeev, A. E. (2022) · Modern Gastroenterology · doi:10.30978/mg-2022-3-50 · Cited by 2
Metadata
- Authors
- Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Michigan Medicine (US)
- Bristol Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Salix Pharmaceuticals (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 22-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149216059
- Cited by
- 1,036
- References
- 21
- Citations by year
- 2026: 51 · 2025: 46 · 2024: 36 · 2023: 56 · 2022: 51 · 2021: 65 · 2020: 56 · 2019: 51 · 2018: 65 · 2017: 74 · 2016: 87 · 2015: 70 · 2014: 95 · 2013: 73 · 2012: 87
- FWCI
- 106.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- rifaximin, gut microbiota, bloating, abdominal pain, stool consistency, symptom relief, antibiotic therapy, IBS pathophysiology, TARGET trial, adverse events
- MeSH terms
- Rifaximin, Aged, Anti-Bacterial Agents, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Rifamycins, Abdominal Pain, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.